Russian Study of the Efficacy and Safety of Tarka in Patients With Hypertension
Launched by ABBOTT · Oct 7, 2005
Trial Information
Current as of September 03, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Hypertension
- Exclusion Criteria:
- • SBP \> 180 mm Hg, DBP \> 114 mm Hg
- • Subject has a hypersensitivity to trandolapril or verapamil
About Abbott
Abbott is a global healthcare company dedicated to improving lives through innovative medical technologies, diagnostics, nutrition, and branded generic pharmaceuticals. With a commitment to advancing health and wellness, Abbott conducts clinical trials to evaluate the safety and efficacy of its diverse portfolio of products, which span multiple therapeutic areas, including cardiovascular, diabetes care, and neurology. The company employs rigorous research methodologies and collaborates with healthcare professionals and institutions worldwide to ensure the highest standards of clinical integrity and patient safety. Abbott's mission is to deliver impactful solutions that enhance patient outcomes and contribute to the advancement of global healthcare.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
North Chicago, Illinois, United States
Patients applied
Trial Officials
Victor Gorin, MD
Study Director
Abbott
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials